ArticleFrontiers in medicine2026
Exploring the prediction model and core genes for coronary artery disease in non-obese steatotic liver disease patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds and aims: Non-obese steatotic liver disease (SLD) refers to a metabolic disorder characterized by ectopic fat deposition in the liver, but without increased subcutaneous adipose tissue and normal body mass index (BMI) in patients. Emerging evidence indicates that non-obese SLD is associated with coronary artery disease (CAD). However, the mechanisms underlying their mutual relationship remain undefined. Methods: We retrospectively analyzed 8,722 subjects and constructed a prediction model for diagnosing CAD in non-obese SLD patients. Then, public datasets from the Gene Expression Omnibus (GEO) were retrieved for further bioinformatics analysis, and machine learning algorithms were used to screen candidate core genes. Results: Through the analysis of clinical data, we found that the risk of CAD in non-obese SLD patients was significantly higher than that in obese SLD patients and individuals without SLD. We constructed a nomogram for predicting CAD in non-obese SLD patients, and the area under the curve for training and validation sets was 0.846 and 0.732, respectively. We analyzed the non-obese SLD dataset (GSE89632) and CAD dataset (GSE113079) and overlapped the differentially expressed genes (DEGs) in these two datasets. We found that there were 28 overlapping upregulated DEGs and 66 overlapping downregulated DEGs. The protein-protein interaction network generated a 94-edge network, and the top 40 hub genes were selected using the maximal clique centrality algorithm. The candidate core genes, including HNF4A and LTBP4, were screened based on machine learning algorithms. The receiver operating characteristic results showed that these two genes have considerable diagnostic value for non-obese SLD and CAD. Conclusion: We found a close correlation between non-obese SLD and CAD. Our study developed a novel diagnostic model to predict CAD in non-obese SLD patients with promising predictive performance. In addition, through comprehensive bioinformatics analysis and machine learning algorithms, two key core genes, HNF4A and LTBP4, were identified to be associated with both non-obese SLD and CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.